W146 TFA|cas:909725-62-8|西域试剂

W146 TFA,98.13%

产品编号：Bellancom-101395A| CAS NO：909725-62-8| 分子式：C₁₈H₂₈F₃N₂O₆P| 分子量：456.39

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-101395A	￥1500.00	杭州北京（现货）
Bellancom-101395A	￥5900.00	杭州北京（现货）
Bellancom-101395A	￥10500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

W146 TFA

产品介绍

W146 TFA 是 1-磷酸-鞘氨醇受体亚型 1 (S1PR1) 的选择性拮抗剂， EC₅₀ 值为 398 nM。

生物活性

W146 TFA is a selective antagonist of sphingosine-1-phosphate receptor 1 (S1PR1) with an EC₅₀ value of 398 nM.

体外研究

W146 is a S1PR1 antagonist with a K_i of ~70-80 nM.
W146 pretreatment significantly increases activated cleaved caspase-3 levels. The reduced EPCs apoptosis which induced by S1P is completely abolished after treatment with W146.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis

Cell Line:	Endothelial progenitor cells (EPCs).
Concentration:	10 μM.
Incubation Time:	30 min before the addition of S1P.
Result:	Increases activated cleaved caspase-3 levels.

体内研究
(In Vivo)

W146 (5 mg/kg, ip, prior to AMD3100 administration) pre-treatment shows approximately 8-fold increase of KSL-HSPC mobilization, measured by the CFU-G/M colony forming assays, compared to that in mice treated with AMD3100 alone
The W146-mediated augmentation of KSL-HSPC mobilization is specific, because pretreatment of mice with W140 is unable to produce any effect on AMD3100-stimulated KSL-HSPC mobilization. Injections of W146, W140, JTE013, or Cay10444 do not alter the basal WBC count in mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Mice (4-6-week-old) .
Dosage:	5 mg/kg.
Administration:	IP, 1 hour prior to AMD3100 (ADM) administration.
Result:	Significantly increased in KSL-HSPC mobilization compared to that in mice pretreated with dextran followed by AMD3100 administration.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Mice (4-6-week-old) .
Dosage:	5 mg/kg.
Administration:	IP, 1 hour prior to AMD3100 (ADM) administration.
Result:	Significantly increased in KSL-HSPC mobilization compared to that in mice pretreated with dextran followed by AMD3100 administration.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Mice (4-6-week-old) .
Dosage:	5 mg/kg.
Administration:	IP, 1 hour prior to AMD3100 (ADM) administration.
Result:	Significantly increased in KSL-HSPC mobilization compared to that in mice pretreated with dextran followed by AMD3100 administration.

性状

Solid

溶解性数据

In Vitro:

DMSO : 55 mg/mL (120.51 mM; ultrasonic and warming and heat to 60°C)

Ethanol : < 1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.1911 mL	10.9555 mL	21.9111 mL
5 mM	0.4382 mL	2.1911 mL	4.3822 mL
10 mM	0.2191 mL	1.0956 mL	2.1911 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, sealed storage, away from moisture and light

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

参考文献